Galectin-3 levels are elevated following nintedanib treatment

BACKGROUND AND AIMS: Idiopathic pulmonary fibrosis (IPF) is a common and severe form of pulmonary fibrosis. Nintedanib, a triple angiokinase inhibitor, is approved for treating IPF. Galectin 3 (Gal-3) activates a variety of profibrotic processes. Currently, the Gal-3 inhibitor TD139 is being tested...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Ther Adv Chronic Dis
Egile Nagusiak: Shochet, Gali Epstein, Pomerantz, Alon, Shitrit, David, Bardenstein-Wald, Becky, Ask, Kjetil, Surber, Mark, Rabinowicz, Noa, Levy, Yair, Benchetrit, Sydney, Edelstein, Evgeny, Zitman-Gal, Tali
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: SAGE Publications 2020
Gaiak:
Original Research
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7907712/
https://ncbi.nlm.nih.gov/pubmed/33708368
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2040622320968412
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak